Jade Biosciences Raises $45M in Private Stock Offering Of 3.21M Shares At $14/Share To Advance Autoimmune Drug Research

Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it has entered into a securities purchase agreement with BB Biotech for a private placement financing that is expected to result in gross proceeds of approximately $45 million to the Company, before offering expenses.

Pursuant to the terms of the securities purchase agreement, Jade is selling an aggregate of 3,214,286 shares of its common stock ("Common Stock") at a purchase price of $14.00 per share. The private placement is expected to close on or about December 16, 2025, subject to satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the private placement to fund research and development, general corporate expenses, and working capital needs.